The Use of FDG Positron Emission Tomography (PET)in Patient With Hodgkin Lymphoma (HL) in the "Real World": a Population Based Study From Northern Italy
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Histologically Confirmed Classical Hodgkin Lymphoma According to the Current World Health Organisation Classification
Both
Histologically Confirmed Classical Hodgkin Lymphoma According to the Current World Health Organisation Classification
Trial Information
The Use of FDG Positron Emission Tomography (PET)in Patient With Hodgkin Lymphoma (HL) in the "Real World": a Population Based Study From Northern Italy
Inclusion Criteria:
1. Histologically confirmed classical Hodgkin lymphoma according to the current World
Health Organisation Classification (nodular sclerosis, mixed cellularity, lymphocyte
rich, lymphocyte depleted).
2. Clinical stage I-IV.
3. No previous chemotherapy, radiotherapy or other investigational drug for HL.
Exclusion Criteria:
1. None.
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Retrospective
Outcome Measure:
Progression-free survival
Outcome Time Frame:
within 1 month after end of treatment
Safety Issue:
No
Principal Investigator
Massimo Federico, MD
Investigator Role:
Study Chair
Investigator Affiliation:
Università di Modena e Reggio Emilia
Authority:
Italy: Ethics Committee
Study ID:
PET-LH
NCT ID:
NCT01248000
Start Date:
May 2009
Completion Date:
May 2010
Related Keywords:
- Histologically Confirmed Classical Hodgkin Lymphoma According to the Current World Health Organisation Classification
- Hodgkin lymphoma
- FDG-PET
- prognostic factor
- clinical trial
- Hodgkin Disease
- Lymphoma
Name | Location |
|---|
